Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Alkermes PLC (ALKS) Insider Trading Activity
Healthcare • Drug Manufacturers - Specialty & Generic • 2,100 employees
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Total Value
-$3,283,289.74
Total Shares
-22,976
Average Trade Value
-$93,808.28
Most Active Insider
Hopkinson Craig C.
Total Activity: $6,751,874
Largest Single Transaction
$1,961,406
by Hopkinson Craig C. on Dec 9, 2024
30-Day Activity
12 Transactions
Volume: 37,727 shares
Value: $1,778,218
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
EVP Rd, Chief Medical Officer
Officer
|
Dec 9, 2024 | 12,090 | $233,821 | 84,272 (+14.3%) | Exercise/Conversion | |
|
Director
|
Dec 9, 2024 | 2,691 | $60,601 | 25,704 (+10.5%) | Exercise/Conversion | |
|
EVP Rd, Chief Medical Officer
Officer
|
Dec 9, 2024 | 61,151 | $1,961,406 | 47,576 (-128.5%) | Sale | |
|
EVP Rd, Chief Medical Officer
Officer
|
Dec 9, 2024 | 12,044 | $296,162 | 96,316 (+12.5%) | Exercise/Conversion | |
|
EVP Rd, Chief Medical Officer
Officer
|
Dec 9, 2024 | 12,452 | $249,414 | 72,182 (+17.3%) | Exercise/Conversion | |
|
Director
|
Dec 9, 2024 | 2,691 | $85,708 | 23,013 (-11.7%) | Sale | |
|
EVP Rd, Chief Medical Officer
Officer
|
Dec 9, 2024 | 12,411 | $332,863 | 108,727 (+11.4%) | Exercise/Conversion | |
|
Director
|
Dec 8, 2024 | 4,163 | $10,000 | 23,971 (+17.4%) | Exercise/Conversion | |
|
Director
|
Dec 8, 2024 | 958 | $30,139 | 23,013 (-4.2%) | Payment of Exercise Price | |
|
EVP Rd, Chief Medical Officer
Officer
|
Dec 5, 2024 | 9,221 | $290,462 | 59,730 (-15.4%) | Sale | |
|
EVP Rd, Chief Medical Officer
Officer
|
Dec 4, 2024 | 14,349 | $441,550 | 68,951 (-20.8%) | Sale | |
|
Svp, Chief Commercial Officer
Officer
|
Nov 27, 2024 | 5,208 | $151,813 | 60,703 (-8.6%) | Sale | |
|
EVP Rd, Chief Medical Officer
Officer
|
Nov 11, 2024 | 58,996 | $1,774,576 | 83,300 (-70.8%) | Sale | |
|
EVP Rd, Chief Medical Officer
Officer
|
Nov 11, 2024 | 43,058 | $862,452 | 142,296 (+30.3%) | Exercise/Conversion | |
|
EVP Rd, Chief Medical Officer
Officer
|
Nov 6, 2024 | 10,471 | $309,169 | 99,238 (-10.6%) | Sale | |
|
Evp, Clo, Alkermes, Inc.
Officer
|
Aug 3, 2024 | 2,014 | $10,000 | 166,796 (+1.2%) | Exercise/Conversion | |
|
Evp, Clo, Alkermes, Inc.
Officer
|
Aug 3, 2024 | 895 | $24,809 | 165,901 (-0.5%) | Payment of Exercise Price | |
|
Director
|
Jun 29, 2024 | 6,104 | $10,000 | 29,245 (+20.9%) | Exercise/Conversion | |
|
Director
|
Jun 29, 2024 | 6,104 | $10,000 | 29,245 (+20.9%) | Exercise/Conversion | |
|
Director
|
Jun 29, 2024 | 6,104 | $10,000 | 28,767 (+21.2%) | Exercise/Conversion | |
|
Director
|
Jun 29, 2024 | 6,104 | $10,000 | 26,460 (+23.1%) | Exercise/Conversion | |
|
Director
|
Jun 29, 2024 | 1,465 | $35,307 | 27,780 (-5.3%) | Payment of Exercise Price | |
|
Director
|
Jun 29, 2024 | 1,465 | $35,307 | 27,302 (-5.4%) | Payment of Exercise Price | |
|
Director
|
Jun 29, 2024 | 1,465 | $35,307 | 14,416 (-10.2%) | Payment of Exercise Price | |
|
Director
|
Jun 29, 2024 | 6,104 | $10,000 | 15,881 (+38.4%) | Exercise/Conversion | |
|
Director
|
Jun 29, 2024 | 1,465 | $35,307 | 24,995 (-5.9%) | Payment of Exercise Price | |
|
Director
|
Jun 29, 2024 | 1,465 | $35,307 | 24,995 (-5.9%) | Payment of Exercise Price | |
|
Director
|
Jun 29, 2024 | 6,104 | $10,000 | 21,273 (+28.7%) | Exercise/Conversion | |
|
Director
|
Jun 29, 2024 | 1,465 | $35,307 | 4,639 (-31.6%) | Payment of Exercise Price | |
|
Director
|
Jun 29, 2024 | 6,104 | $10,000 | 6,104 (+100.0%) | Exercise/Conversion | |
|
Director
|
Jun 29, 2024 | 3,175 | $76,518 | 99,906 (-3.2%) | Payment of Exercise Price | |
|
Director
|
Jun 29, 2024 | 6,104 | $10,000 | 26,460 (+23.1%) | Exercise/Conversion | |
|
Director
|
Jun 29, 2024 | 6,104 | $10,000 | 103,081 (+5.9%) | Exercise/Conversion | |
|
Director
|
Jun 29, 2024 | 1,465 | $35,307 | 27,780 (-5.3%) | Payment of Exercise Price | |
|
Director
|
Jun 29, 2024 | 1,465 | $35,307 | 19,808 (-7.4%) | Payment of Exercise Price |